Lipoprotein apheresis
Patrick M Moriarty1, Linda Hemphill2
1Division of Clinical Pharmacology and Atherosclerosis/Lipoprotein-Apheresis Center, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3008, Kansas City, KS 66160, USA.
Insights
Lipoprotein apheresis (LA) effectively lowers low-density lipoprotein cholesterol (LDL-C) and reduces cardiovascular events in familial hypercholesterolemia (FH) patients. This therapy also decreases Lp(a) levels, inflammatory markers, and blood viscosity.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Medical Technology
Background:
- Familial hypercholesterolemia (FH) accelerates atherosclerosis and cardiovascular disease (CVD).
- Standard lipid-lowering drugs may not sufficiently reduce elevated low-density lipoprotein cholesterol (LDL-C).
- Lipoprotein apheresis (LA) is an extracorporeal therapy for managing severe hypercholesterolemia.
Purpose of the Study:
- To evaluate the clinical efficacy of Lipoprotein apheresis (LA) in patients with familial hypercholesterolemia (FH).
- To assess the impact of LA on cardiovascular disease (CVD) events and key lipid parameters.
Main Methods:
- Lipoprotein apheresis (LA) therapy was administered to patients diagnosed with FH.
- Treatment outcomes included changes in LDL-C, Lp(a) levels, and incidence of CVD events.
Main Results:
- LA therapy significantly reduced LDL-C levels by over 60% in FH patients.
- LA demonstrated a reduction in cardiovascular disease (CVD) events.
- The therapy also led to decreased levels of Lp(a), inflammatory markers, and blood viscosity.
Conclusions:
- Lipoprotein apheresis (LA) is a clinically beneficial therapy for managing familial hypercholesterolemia (FH).
- LA effectively reduces LDL-C and Lp(a) levels, contributing to a decrease in cardiovascular events.
- LA offers additional benefits by reducing inflammatory markers and improving hemorheological properties.
Abstract:
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients with FH with hypercholesterolemia. LA reduces LDL-C levels by more than 60% in patients with FH and reduces CVD events. LA also reduces Lp(a) levels and CVD events. LA reduces inflammatory markers and blood viscosity.
